Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MMP9 | P14780 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | VCP | P55072 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1876416 | 0.66 | KDM4E (0.35) | ALDH1A1KDM4EUSP2LMNAMMP9 | |
| SCHEMBL1878342 | 0.66 | HSD11B1 (0.45) | ALDH1A1KDM4EUSP2LMNAMMP9 | |
| SCHEMBL7220330 | 0.63 | TSHR (0.62) | ALDH1A1KDM4EUSP2LMNAMMP9 | |
| SCHEMBL1877771 | 0.63 | DRD3 (0.45) | ALDH1A1KDM4EUSP2LMNAMMP9 | |
| SCHEMBL1871523 | 0.62 | HSD11B1 (0.35) | ALDH1A1KDM4EUSP2LMNAMMP9 | |
| SCHEMBL11252152 | 0.61 | TSHR (0.58) | ALDH1A1KDM4EUSP2LMNAMMP9 | |
| SCHEMBL2054710 | 0.61 | ALDH1A1 (0.41) | ALDH1A1ALOX15TSHRKMT2AMEN1 | |
| Busulfan SCHEMBL4373 | 0.60 | TSHR (1.00) | ALDH1A1KDM4EUSP2LMNAMMP9 | |
| Busulfan SCHEMBL4764696 | 0.60 | TSHR (1.00) | ALDH1A1KDM4EUSP2LMNAMMP9 | |
| SCHEMBL31704435 | 0.58 | TSHR (0.54) | ALDH1A1KDM4EUSP2LMNAMMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7947683-B2 | 3-(1,2,4-triazol-3-ylalkyl) azabicyclo (3.1.0) hexane derivatives as modulators of dopamine D3 receptors | GLAXO GROUP LIMTED (GB) | 2011-05-24 | — | — | US | disclosed |
| US-20090124629-A1 | 3-(1,2,4-TRIAZOL-3YLALKYL) AZABRICLO (3.1.0) HEXANE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2009-05-14 | — | — | US | disclosed |
| EP-1869017-A1 | 3- (1,2,4-TRIAZOL-3YLALKYL) AZABRICLO (3.1.0) HEXANE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2007-12-26 | — | — | EP | disclosed |
| WO-2006108701-A1 | 3- (1,2,4-TRIAZOL-3YLALKYL) AZABRICLO (3.1.0) HEXANE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124629-A1 | 3-(1,2,4-TRIAZOL-3YLALKYL) AZABRICLO (3.1.0) HEXANE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS | DRD3, HTR3C, TACR2 | ALDH1A1 2591/4885KDM4E 3100/4885USP2 3466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.